ArticleJournal of virology2002
In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins.
Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 139 citations in OpenAlex.
- Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Emerging trends in virus and virus-like particle gene therapy delivery to the brain.Molecular therapy. Nucleic acids · 2024Review
- Article
- Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering.Journal for immunotherapy of cancer · 2023Article
- Generation of Stable Cell Lines Expressing Golgi Reassembly Stacking Proteins (GRASPs) by Viral Transduction.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Genome-wide integration site detection using Cas9 enriched amplification-free long-range sequencing.Nucleic acids research · 2021Article
- Review
- New Directions in Pulmonary Gene Therapy.Human gene therapy · 2020Review
- Novel GP64 envelope variants for improved delivery to human airway epithelial cells.Gene therapy · 2017Article
- Lentiviral Vectors Pseudotyped with Filoviral Glycoproteins.Methods in molecular biology (Clifton, N.J.) · 2017Article
- Pseudotyping of lentiviral vector with novel vesiculovirus envelope glycoproteins derived from Chandipura and Piry viruses.Virology · 2016Article
- Retinal transduction profiles by high-capacity viral vectors.Gene therapy · 2014Article
- Package of NDV-pseudotyped HIV-Luc virus and its application in the neutralization assay for NDV infection.PloS one · 2014Article
- Histone deacetylase inhibition rescues gene knockout levels achieved with integrase-defective lentiviral vectors encoding zinc-finger nucleases.Human gene therapy methods · 2013Article
- Article
- Venezuelan equine encephalitis virus glycoprotein pseudotyping confers neurotropism to lentiviral vectors.Gene therapy · 2013Article
- Intrapulmonary Versus Nasal Transduction of Murine Airways With GP64-pseudotyped Viral Vectors.Molecular therapy. Nucleic acids · 2013Article
- Innocuous full-length botulinum neurotoxin targets and promotes the expression of lentiviral vectors in central and autonomic neurons.Gene therapy · 2011Article
- Altering α-dystroglycan receptor affinity of LCMV pseudotyped lentivirus yields unique cell and tissue tropism.Genetic vaccines and therapy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
Abstract
Vectors derived from lentiviruses provide a promising gene delivery system. We examined the in vivo gene transfer efficiency and tissue or cell tropism of a feline immunodeficiency virus (FIV)-based lentiviral vector pseudotyped with the glycoproteins from Ross River Virus (RRV). RRV glycoproteins were efficiently incorporated into FIV virions, generating preparations of FIV vector, which after concentration attain titers up to 1.5 x 10(8) TU/ml. After systemic administration, RRV-pseudotyped FIV vectors (RRV/FIV) predominantly transduced the liver of recipient mice. Transduction efficiency in the liver with the RRV/FIV was ca. 20-fold higher than that achieved with the vesicular stomatitis virus G protein (VSV-G) pseudotype. Moreover, in comparison to VSV-G, the RRV glycoproteins caused less cytotoxicity, as determined from the levels of glutamic pyruvic transaminase and glutamic oxalacetic transaminase in serum. Although hepatocytes were the main liver cell type transduced, nonhepatocytes (mainly Kupffer cells) were also transduced. The percentages of the transduced nonhepatocytes were comparable between RRV and VSV-G pseudotypes and did not correlate with the production of antibody against the transgene product. After injection into brain, RRV/FIV preferentially transduced neuroglial cells (astrocytes and oligodendrocytes). In contrast to the VSV-G protein that targets predominantly neurons, <10% of the brain cells transduced with the RRV pseudotyped vector were neurons. Finally, the gene transfer efficiencies of RRV/FIV after direct application to skeletal muscle or airway were also examined and, although transgene-expressing cells were detected, their proportions were low. Our data support the utility of RRV glycoprotein-pseudotyped FIV lentiviral vectors for hepatocyte- and neuroglia-related disease applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.